T here’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.
Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.
More From Other Publishers How much is Biogen’s spinoff really worth? STAT This tech won the Nobel Prize — and drug developers are avidly putting it to use STAT 5 reasons why no one has built a better EpiPen STAT Reporter's notebook: A surge of unexpected optimism around CAR-T STAT New drugs, wearable trackers, and a Narcan mask: Ohio tech fund inspires new ideas to fight the opioid crisis STAT
With deadlines looming, pharma companies look to tighten drug security STAT Biotechs anxious as Massachusetts retools growth plan STAT The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer's drug STAT Dx Executives Hopeful for Improved Regulation, More Product Development Funding 360Dx, 2016 Potassium Drug Denied Again (Endpoints News) MedPage Today, 2017
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.